Spyre Therapeutics, Inc.
SYREDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 4, 2026
6dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
SYRE Earnings Report
EPS Est: $-0.71 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SYRE's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPY002-072 | Phase 2 | Rheumatoid Arthritis | - | - |
SPY001 | Phase 2 | Ulcerative Colitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Spyre Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Spyre Therapeutics, Inc.'s (SYRE) pipeline across Phase 2. Its lead program is SPY002-072 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Spyre Therapeutics, Inc.'s next FDA catalyst?→
Spyre Therapeutics, Inc.'s (SYRE) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SYRE biotech catalysts?→
Add SYRE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Spyre Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.